OmniAb Inc
Research OmniAb Inc (OABI) on Bullrun: market cap USD 677.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOABI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 677.52M
- Financial periodQ2 2026
- RevenueUSD 13.42M
- Net income-USD 5.86M
- Free cash flowUSD 2.57M
- Gross margin95.5%
Valuation Snapshot
latest market cap is USD 677.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 18.67M | -USD 64.78M | -USD 37.02M | 98.4% | -0.57 | USD 25.52M | USD 20.33M | USD 267.03M |
| FY2024 | USD 26.39M | -USD 62.03M | -USD 41.54M | n/a | -0.61 | USD 27.60M | USD 23.16M | USD 287.62M |
| FY2023 | USD 34.16M | -USD 50.62M | USD 703.00K | n/a | -0.51 | USD 16.36M | USD 25.56M | USD 314.59M |
| FY2022 | USD 59.08M | -USD 22.33M | -USD 20.76M | n/a | -0.26 | USD 33.39M | USD 26.64M | USD 341.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 677.52M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 266.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 430.46M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 717.57M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 414.47M | n/a | n/a | n/a |
About OmniAb Inc
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OmniAb Inc's market cap?
OmniAb Inc's market capitalization is USD 677.52M.
What does OmniAb Inc do?
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.